Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
Status:
Completed
Trial end date:
2018-10-22
Target enrollment:
Participant gender:
Summary
This study was to determine early and more chronic changes in concentrations of biomarkers
related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a
period of 12 months, and correlated these biomarker changes with cardiac remodeling
parameters, patient-reported outcomes and cardiovascular outcomes.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan